1
|
Cozlac AR, Streian CG, Boca MI, Crisan S, Lazar MA, Virtosu MD, Ionac A, Staicu RE, Dugaci DC, Emandi-Chirita A, Lascu A, Gaita D, Luca CT. A Dual Challenge: Coxiella burnetii Endocarditis in a Patient with Familial Thoracic Aortic Aneurysm-Case Report and Literature Review. J Clin Med 2024; 13:7155. [PMID: 39685614 DOI: 10.3390/jcm13237155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2024] [Revised: 11/14/2024] [Accepted: 11/22/2024] [Indexed: 12/18/2024] Open
Abstract
Background/Objectives: Thoracic aortic aneurysms (TAAs) are potentially life-threatening medical conditions, and their etiology involves both genetic and multiple risk factors. Coxiella burnetii endocarditis is one of the most frequent causes of blood culture-negative infective endocarditis (BCNIE) in patients with previous cardiac surgery. Our review aims to emphasize the importance of genetic testing in patients with thoracic aortic aneurysms but also the importance of additional testing in patients with suspected endocarditis whose blood cultures remain negative. The reported case has a history of acute DeBakey type I aortic dissection that developed during her second pregnancy, for which the Bentall procedure was performed at that time. Ten years after the surgery, the patient started developing prolonged febrile syndrome with repeatedly negative blood cultures, the serological tests revealing the presence of an infection with Coxiella burnetii. Considering her family history and the onset of her aortic pathology at a young age, genetic tests were performed, disclosing a missense variant in the actin alpha-2 (ACTA2) gene in heterozygous status. Methods: For a better understanding of both conditions, our research was conducted in two directions: one reviewing the literature on patients with Coxiella burnetii BCNIE and the other focusing on patients who had a familial thoracic aortic aneurysm (FTAA) due to the ACTA2 variant. This review incorporates studies found on PubMed and ResearchGate up to August 2024. Conclusions: BCNIE represents a condition with several diagnostic challenges and may lead to severe complications if timely treatment is not initiated. Also, diagnosing an FTAA requires genetic testing, enabling better follow-up and management.
Collapse
Affiliation(s)
- Alina-Ramona Cozlac
- Department VI Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Advanced Research Center of the Institute for Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Caius Glad Streian
- Department VI Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Advanced Research Center of the Institute for Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Marciana Ionela Boca
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
| | - Simina Crisan
- Department VI Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Advanced Research Center of the Institute for Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Mihai-Andrei Lazar
- Department VI Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Advanced Research Center of the Institute for Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Mirela-Daniela Virtosu
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Department VI Cardiology Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babeș" University of Medicine and Pharmacy of Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Doctoral School Medicine-Pharmacy, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Adina Ionac
- Department VI Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Advanced Research Center of the Institute for Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Raluca Elisabeta Staicu
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Doctoral School Medicine-Pharmacy, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Daniela-Carmen Dugaci
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
| | - Adela Emandi-Chirita
- Centre of Genomic Medicine, Genetics Discipline, "Victor Babeș" University of Medicine and Pharmacy of Timișoara, 300041 Timisoara, Romania
| | - Ana Lascu
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Department III Functional Sciences-Pathophysiology, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Centre for Translational Research and Systems Medicine, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Dan Gaita
- Department VI Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Advanced Research Center of the Institute for Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| | - Constantin-Tudor Luca
- Department VI Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
- Institute for Cardiovascular Diseases of Timisoara, "Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam Str. No. 13A, 300310 Timisoara, Romania
- Advanced Research Center of the Institute for Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
| |
Collapse
|
2
|
Liu T, Zhang T, Guo C, Liang X, Wang P, Zheng B. Murine double minute 2-mediated estrogen receptor 1 degradation activates macrophage migration inhibitory factor to promote vascular smooth muscle cell dedifferentiation and oxidative stress during thoracic aortic aneurysm progression. BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH 2024; 1871:119661. [PMID: 38218386 DOI: 10.1016/j.bbamcr.2024.119661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 12/19/2023] [Accepted: 01/03/2024] [Indexed: 01/15/2024]
Abstract
Estrogen receptor 1 (ESR1) has been recently demonstrated as a potential diagnostic biomarker for thoracic aortic aneurysm (TAA). However, its precise role in the progression of TAA remains unclear. In this study, TAA models were established in ApoE-knockout mice and primary mouse vascular smooth muscle cells (VSMCs) through treatment with angiotensin (Ang) II. Our findings revealed a downregulation of ESR1 in Ang II-induced TAA mice and VSMCs. Upregulation of ESR1 mitigated expansion and cell apoptosis in the mouse aorta, reduced pathogenetic transformation of VSMCs, and reduced inflammatory infiltration and oxidative stress both in vitro and in vivo. Furthermore, we identified macrophage migration inhibitory factor (MIF) as a biological target of ESR1. ESR1 bound to the MIF promoter to suppress its transcription. Artificial MIF restoration negated the mitigating effects of ESR1 on TAA. Additionally, we discovered that murine double minute 2 (MDM2) was highly expressed in TAA models and mediated protein degradation of ESR1 through ubiquitination modification. Silencing of MDM2 reduced VSMC dedifferentiation and suppressed oxidative stress. However, these effects were reversed upon further silencing of ESR1. In conclusion, this study demonstrates that MDM2 activates MIF by mediating ESR1 degradation, thus promoting VSMC dedifferentiation and oxidative stress during TAA progression.
Collapse
Affiliation(s)
- Tao Liu
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, PR China; Department of Cardiovascular Surgery, Guangxi International Zhuang Medicine Hospital, Guangxi University of Chinese Medicine, Nanning 530001, Guangxi, PR China
| | - Tian Zhang
- Department of Cardiovascular Surgery, Guangxi International Zhuang Medicine Hospital, Guangxi University of Chinese Medicine, Nanning 530001, Guangxi, PR China
| | - Chenfan Guo
- Department of Cardiovascular Surgery, Guangxi International Zhuang Medicine Hospital, Guangxi University of Chinese Medicine, Nanning 530001, Guangxi, PR China
| | - Xiangsen Liang
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, Guangxi, PR China
| | - Pandeng Wang
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, PR China.
| | - Baoshi Zheng
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, PR China.
| |
Collapse
|
3
|
Mahlmann A, Elzanaty N, Saleh M, Irqsusi M, Rastan A, Leip JL, Behrendt CA, Ghazy T. Prevalence of Genetic Variants and Deep Phenotyping in Patients with Thoracic Aortic Aneurysm and Dissection: A Cross-Sectional Single-Centre Cohort Study. J Clin Med 2024; 13:461. [PMID: 38256594 PMCID: PMC10816602 DOI: 10.3390/jcm13020461] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 01/05/2024] [Accepted: 01/11/2024] [Indexed: 01/24/2024] Open
Abstract
BACKGROUND There is a paucity of evidence on people with thoracic aortic aneurysm and dissection. We aimed to determine the prevalence of genetic variants and their associations with phenotypes. METHODS In this cross-sectional single-centre cohort study of consecutive patients who underwent endovascular or open-surgical repair of thoracic aortic aneurysm and dissection, genetic analysis was performed using four-stage Next Generation Sequencing, and findings were confirmed with Sanger sequencing. We collected personal and family history on comorbidities, clinical examination, anthropometrics, skeletal deformities, joint function, and ophthalmological measures. Cardiovascular risk and phenotype scores were calculated. RESULTS Ninety-five patients were eligible (mean age 54 ± 9 years, 70% males, 56% aortic dissection). One-fifth had a family history of aortic disease. Furthermore, 95% and 54% had a phenotype score of ≤5 and ≤2, respectively. There were no significant differences in the distribution of phenotype characteristics according to age, sex, aortic pathology, or performed invasive procedures. Genetic variants of uncertain significance were detected in 40% of patients, with classic mutations comprising 18% of all variants. We observed no significant association with cardiovascular and phenotype scores but with higher joint function scores (p = 0.015). CONCLUSION Genetic variants are highly present in clinically relevant aortic pathologies. Variants appear to play a larger role than previously described. The different variants do not correlate with specific phenotypes, age, pathology, sex, or family history.
Collapse
Affiliation(s)
- Adrian Mahlmann
- Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany;
- Centre for Vascular Medicine, Clinic of Angiology, St.-Josefs-Hospital, Katholische Krankenhaus Hagen gem. GmbH, 58097 Hagen, Germany
| | - Nesma Elzanaty
- Department of Medical Physiology, Tanta Faculty of Medicine, Tanta University, Tanta 31527, Egypt;
| | - Mai Saleh
- Department of Chest Diseases, Tanta Faculty of Medicine, Tanta University, Tanta 31527, Egypt;
| | - Marc Irqsusi
- Department of Cardiac Surgery, Marburg University Hospital, Philipps University of Marburg, 35043 Marburg, Germany; (M.I.); (A.R.)
| | - Ardawan Rastan
- Department of Cardiac Surgery, Marburg University Hospital, Philipps University of Marburg, 35043 Marburg, Germany; (M.I.); (A.R.)
| | | | - Christian-Alexander Behrendt
- Department of Vascular and Endovascular Surgery, Asklepios Clinic Wandsbek, Asklepios Medical School, 20099 Hamburg, Germany;
- Brandenburg Medical School Theodor Fontane, 16816 Neuruppin, Germany
| | - Tamer Ghazy
- Department of Cardiac Surgery, Marburg University Hospital, Philipps University of Marburg, 35043 Marburg, Germany; (M.I.); (A.R.)
| |
Collapse
|
5
|
Abstract
Aortic aneurysms were the primary cause of nearly 10,000 deaths in 2014 according to data from the Centers for Disease Control and may involve segments of the thoracic or abdominal aorta. Thoracic aortic aneurysms and dissections are more commonly associated with an underlying genetic etiology. In the past several decades, in parallel with the burst of new genome sequencing technologies, a number of genetic aortopathies have been identified. These have provided important insights into the molecular mechanisms of aneurysmal disease, but pose challenges in clinical practice as there are limited consensus recommendations at this time. In this review, we aim to address the pathophysiology, clinical presentation, and treatment considerations in the key heritable thoracic aortopathies.
Collapse
Affiliation(s)
- Rohan Bhandari
- Department of Cardiovascular Medicine, Section of Vascular Medicine, Cleveland Clinic, Cleveland, OH, USA
| | - Rajani D Aatre
- Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA
| | - Yogendra Kanthi
- Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA.,Cardiovascular Medicine, Ann Arbor Veterans Affairs Health System, Ann Arbor, MI, USA
| |
Collapse
|
6
|
Keravnou A, Bashiardes E, Barberis V, Michailidou K, Soteriou M, Tanteles GA, Cariolou MA. Identification of novel splice mutation in SMAD3 in two Cypriot families with nonsyndromic thoracic aortic aneurysm. Two case reports. Mol Genet Genomic Med 2020; 8:e1378. [PMID: 32597575 PMCID: PMC7507478 DOI: 10.1002/mgg3.1378] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 05/21/2020] [Accepted: 06/01/2020] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Thoracic aortic aneurysm and dissection (TAA/D) represents a potentially lethal disease group characterized by an increased risk of dissection or rupture. Only a small percentage (approximately 30%) of individuals with nonsyndromic familial TAA/D have a pathogenic variant in one of the genes that have been found to be associated with the disease. METHODS A targeted sequencing panel and direct sequencing approach were used to identify causative mutations in the index patients and other family members. RESULTS In this study we report two apparently unrelated Cypriot families with nonsyndromic familial TAA/D. The proband A is a female patient diagnosed with TAA/D and intracranial aneurysm and opted for an elective intervention. The proband B is a male patient who was diagnosed with TAA/D and underwent cardiac surgery. Sequencing analysis identified a novel splice site variant (c.871+1G>A) in SMAD3 which is shown to be associated with the disease. Analysis of mRNA from the patient's tissue confirmed aberrant splicing and exon 6 skipping. CONCLUSION Our findings expand the mutation spectrum of variants that have been shown to be associated with nonsyndromic familial TAA/D. This study demonstrates the importance of a comprehensive clinical and genetic evaluation aiming at early diagnosis and intervention.
Collapse
Affiliation(s)
- Anna Keravnou
- Department of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.,Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| | - Evy Bashiardes
- Department of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.,Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| | - Vassilis Barberis
- Department of Cardiology and Cardiovascular Surgery, American Medical Center, Nicosia, Cyprus
| | - Kyriaki Michailidou
- Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.,Biostatistics Unit, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
| | - Marinos Soteriou
- Department of Cardiology and Cardiovascular Surgery, American Medical Center, Nicosia, Cyprus
| | - George A Tanteles
- Clinical Genetics Clinic, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
| | - Marios A Cariolou
- Department of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.,Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| |
Collapse
|